Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999685316> ?p ?o ?g. }
- W2999685316 abstract "Abstract Background Three anti-TNFs (one intravenous and two subcutaneous) are licensed for the treatment of ulcerative colitis (UC). However, it is not known if the efficacy of a second anti-TNF changes on whether it is intravenous or subcutaneous; this could justify the indication of biological agents with a different mechanism of action in second line. The aim of this study was to compare the efficacy of a second subcutaneous or intravenous anti-TNF in UC. Methods Patients from the prospectively maintained ENEIDA registry treated with consecutively intravenous and subcutaneous anti-TNF, who were naïve to biological agents, were identified. Patients were classified according to the administration route of the first anti-TNF in: IVi (intravenous initially) or SCi (subcutaneous initially). Patients treated for extraintestinal manifestations or pouchitis were excluded. Clinical activity and effectiveness were defined based on Partial Mayo Score (PMS) at baseline, 14 and 52 weeks. Loss of response, dose-escalation and treatment discontinuation were also assessed. Results 372 UC patients were included (270 IVi and 102 SCi). Both cohorts were similar in clinical-epidemiological characteristics, except for a higher proportion of patients with moderate-to-severe clinical activity at the beginning of the first anti-TNF in the IVi group (82% vs. 71%; p = 0.017) and at the beginning of the second anti-TNF (62% vs. 74%; p = 0.04). Clinical response and remission rates at week 14 for the second anti-TNF were 41% and 29% in IVi vs. 47% and 25% in SCi, respectively (p = ns). At week 52, clinical response/remission rates of the second anti-TNF were 37%/32% in IVi vs. 40%/29% in SCi (p = ns). A higher response rate at 14 weeks with the second anti-TNF was detected in the SCi group (40% vs. 68%; p = 0.012) when the reason for withdrawal of the first anti-TNF was secondary loss of response. The cumulative persistence of the second anti-TNF treatment in IVi and SCi were 55% and 54% after 1 year, and 41% and 40% after 2 years, respectively (p = ns). The SCi group had lower rates of dose-escalation with the second anti-TNF than IVi (34% and 29% in SCi vs. 57% and 49% in EVi, at 12 and 24 months, respectively -p = 0.004-). Dose-escalation of the first anti-TNF and moderate-to-severe clinical activity at the beginning of the second anti-TNF were associated with a lower probability of remission with the second anti-TNF in the short- and long-term. Conclusion The efficacy of infliximab after failure/intolerance of a subcutaneous anti-TNF is similar to that of subcutaneous anti-TNFs after infliximab failure/intolerance." @default.
- W2999685316 created "2020-01-23" @default.
- W2999685316 creator A5008521272 @default.
- W2999685316 creator A5009906875 @default.
- W2999685316 creator A5012239601 @default.
- W2999685316 creator A5014254734 @default.
- W2999685316 creator A5015851440 @default.
- W2999685316 creator A5017633547 @default.
- W2999685316 creator A5022446788 @default.
- W2999685316 creator A5023291769 @default.
- W2999685316 creator A5023730578 @default.
- W2999685316 creator A5030861583 @default.
- W2999685316 creator A5037542727 @default.
- W2999685316 creator A5038265124 @default.
- W2999685316 creator A5038494190 @default.
- W2999685316 creator A5041633282 @default.
- W2999685316 creator A5041654625 @default.
- W2999685316 creator A5042665707 @default.
- W2999685316 creator A5043088480 @default.
- W2999685316 creator A5046789127 @default.
- W2999685316 creator A5048489661 @default.
- W2999685316 creator A5048672760 @default.
- W2999685316 creator A5050136128 @default.
- W2999685316 creator A5050986258 @default.
- W2999685316 creator A5051384114 @default.
- W2999685316 creator A5053129179 @default.
- W2999685316 creator A5053929337 @default.
- W2999685316 creator A5056652716 @default.
- W2999685316 creator A5058442099 @default.
- W2999685316 creator A5059193792 @default.
- W2999685316 creator A5064167457 @default.
- W2999685316 creator A5067218858 @default.
- W2999685316 creator A5067308357 @default.
- W2999685316 creator A5068603784 @default.
- W2999685316 creator A5077137875 @default.
- W2999685316 creator A5081249346 @default.
- W2999685316 creator A5081687115 @default.
- W2999685316 creator A5083953774 @default.
- W2999685316 creator A5088596171 @default.
- W2999685316 creator A5089006129 @default.
- W2999685316 creator A5089237494 @default.
- W2999685316 creator A5091186900 @default.
- W2999685316 date "2020-01-01" @default.
- W2999685316 modified "2023-10-08" @default.
- W2999685316 title "P544 Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry" @default.
- W2999685316 doi "https://doi.org/10.1093/ecco-jcc/jjz203.672" @default.
- W2999685316 hasPublicationYear "2020" @default.
- W2999685316 type Work @default.
- W2999685316 sameAs 2999685316 @default.
- W2999685316 citedByCount "0" @default.
- W2999685316 crossrefType "journal-article" @default.
- W2999685316 hasAuthorship W2999685316A5008521272 @default.
- W2999685316 hasAuthorship W2999685316A5009906875 @default.
- W2999685316 hasAuthorship W2999685316A5012239601 @default.
- W2999685316 hasAuthorship W2999685316A5014254734 @default.
- W2999685316 hasAuthorship W2999685316A5015851440 @default.
- W2999685316 hasAuthorship W2999685316A5017633547 @default.
- W2999685316 hasAuthorship W2999685316A5022446788 @default.
- W2999685316 hasAuthorship W2999685316A5023291769 @default.
- W2999685316 hasAuthorship W2999685316A5023730578 @default.
- W2999685316 hasAuthorship W2999685316A5030861583 @default.
- W2999685316 hasAuthorship W2999685316A5037542727 @default.
- W2999685316 hasAuthorship W2999685316A5038265124 @default.
- W2999685316 hasAuthorship W2999685316A5038494190 @default.
- W2999685316 hasAuthorship W2999685316A5041633282 @default.
- W2999685316 hasAuthorship W2999685316A5041654625 @default.
- W2999685316 hasAuthorship W2999685316A5042665707 @default.
- W2999685316 hasAuthorship W2999685316A5043088480 @default.
- W2999685316 hasAuthorship W2999685316A5046789127 @default.
- W2999685316 hasAuthorship W2999685316A5048489661 @default.
- W2999685316 hasAuthorship W2999685316A5048672760 @default.
- W2999685316 hasAuthorship W2999685316A5050136128 @default.
- W2999685316 hasAuthorship W2999685316A5050986258 @default.
- W2999685316 hasAuthorship W2999685316A5051384114 @default.
- W2999685316 hasAuthorship W2999685316A5053129179 @default.
- W2999685316 hasAuthorship W2999685316A5053929337 @default.
- W2999685316 hasAuthorship W2999685316A5056652716 @default.
- W2999685316 hasAuthorship W2999685316A5058442099 @default.
- W2999685316 hasAuthorship W2999685316A5059193792 @default.
- W2999685316 hasAuthorship W2999685316A5064167457 @default.
- W2999685316 hasAuthorship W2999685316A5067218858 @default.
- W2999685316 hasAuthorship W2999685316A5067308357 @default.
- W2999685316 hasAuthorship W2999685316A5068603784 @default.
- W2999685316 hasAuthorship W2999685316A5077137875 @default.
- W2999685316 hasAuthorship W2999685316A5081249346 @default.
- W2999685316 hasAuthorship W2999685316A5081687115 @default.
- W2999685316 hasAuthorship W2999685316A5083953774 @default.
- W2999685316 hasAuthorship W2999685316A5088596171 @default.
- W2999685316 hasAuthorship W2999685316A5089006129 @default.
- W2999685316 hasAuthorship W2999685316A5089237494 @default.
- W2999685316 hasAuthorship W2999685316A5091186900 @default.
- W2999685316 hasBestOaLocation W29996853161 @default.
- W2999685316 hasConcept C126322002 @default.
- W2999685316 hasConcept C141071460 @default.
- W2999685316 hasConcept C17991360 @default.
- W2999685316 hasConcept C2775862500 @default.
- W2999685316 hasConcept C2776390293 @default.
- W2999685316 hasConcept C2777138892 @default.
- W2999685316 hasConcept C2778715236 @default.
- W2999685316 hasConcept C2779134260 @default.